Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $34
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $32 to $34.
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $32 to $34.